Rapport Therapeutics, Inc. Common Stock (RAPP) Stock
Key stats
- Market cap
- $1.43B
- Price / Earnings ratio
- -8.9x
- EPS (TTM)
- -$3.03
- Volume
- Loading
- 52-week high
- $52.93
- 52-week low
- $22.06
Source: third-party data provider, as of November 5, 2026
Compare with RAPP
Recent news

Rapport Therapeutics Reports Q3 2026 Net Loss of $40.2 Million
Rapport Therapeutics Reports Q3 2026 Net Loss of $40.2 Million
RAPP

Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
RAPP

RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
RAPP

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
RAPP
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.59
- MACD 12/26/9
- -2.71
- EMA 9 of MACD
- -3.10
- MACD histogram
- 0.40
- SMA 50
- $35.26
- Price below SMA 50
- EMA 50
- $32.64
- Price below EMA 50
- SMA 200
- $35.63
- Price below SMA 200
- EMA 200
- $33.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Rapport Therapeutics Reports Q3 2026 Net Loss of $40.2 Million
Rapport Therapeutics Reports Q3 2026 Net Loss of $40.2 Million
RAPP

Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
RAPP

RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
RAPP

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
RAPP

Biotech Stocks Dive As Top 2% Names Take Hardest Hit
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
RAPP

4 Biotech Stocks With Key Clinical Readouts Expected This Fall
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
RAPP

The 3 Best Healthcare Stocks to Buy in August 2024
The 3 Best Healthcare Stocks to Buy in August 2024
RAPP

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
RAPP

J&J-backed Rapport Therapeutics raises $136 mln in US IPO
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
RAPP

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
RAPP
News tone: automated (AI) classification of the article's content, not a price prediction.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 5, 2026
Technical indicators
- RSI 14
- 40.59
- MACD 12/26/9
- -2.71
- EMA 9 of MACD
- -3.10
- MACD histogram
- 0.40
- SMA 50
- $35.26
- Price below SMA 50
- EMA 50
- $32.64
- Price below EMA 50
- SMA 200
- $35.63
- Price below SMA 200
- EMA 200
- $33.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $71.33
- High
- $89.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.8 | -23.7 | +3.2 |



